100,000 events was performed using either the Cyan ADP (Dako, Denmark) or BD LSRFortessa (BD Biosciences, NJ, USA) flow-cytometers. Data analysis was performed with Summit v4.3 software (Beckman Coulter, CA, USA).
Immunostaining
Lungs or tumors were embedded in O.C.T. (Sakura, Japan) and subsequently frozen at -80°C. Tissue sections (12 µm thick) were prepared using Leica CM 1950 microtome (Leica, Germany) . Sections were fixed in cold acetone for 15 minutes. Fixed samples were stained for lymphatic vessels using anti-LYVE-1 antibodies (Abcam, United Kingdom) followed by secondary Cy-3-conjugated antibodies (Jackson Immunoresearch Laboratories, PA, USA) or hamster anti-mouse podoplanin, biotin-conjugated antibodies (Biolegend) followed by Cy3-conjugated avidin (Jackson ImmunoResearch). Nuclei were stained with DAPI (Electron Microscopy Sciences, PA, USA). Tumor sections were immunostained with anti-cathepsin B antibodies (Abcam, United Kingdom) followed by secondary Dylight 488-conjugated antibodies (Jackson Immunoresearch Laboratories, PA, USA). For the detection of angiogenesis in tumors, tumor sections were immunostained with anti-CD31 antibodies, a specific endothelial cell marker (1:200, BD Biosciences) followed by a Cy3-conjugated secondary antibodies (1:500, Jackson immunoresearch laboratories). For the detection of metastasis, fixed lung samples were stained with hematoxylin and eosin (H&E). Human tumor specimens were embedded in paraffin and sectioned (6-10 µm thick). Sections were stained with mouse anti-human VEGF-C antibodies (R&D systems) and secondary anti-mouse peroxidase-conjugated antibodies (Jackson ImmunoResearch) followed by AEC staining (Nichirei Biosciences Inc., Japan). Images were acquired with a camera attached to an inverted microscope (Leica CTR 6000) using Leica Application suite Version 3.4.0 software. Positive staining was determined by Adobe Photoshop 6 (San Jose, CA), and the number or percentage of positive pixels were plotted.
Conditioned medium of macrophage cultures
Eight-to-ten week old, female, Balb/c mice were induced with thioglycolate (4% in saline). Seventy two hours later, mice were treated with PTX and/or 31C1, MF1, or DC101. After 24 hours, macrophages were collected by peritoneal lavage. Collected macrophages were cultured in serum-free RPMI-1640 media at a concentration of 5x10 6 /ml, and conditioned medium was collected 48 hours later. To obtain conditioned medium from human macrophages, human peripheral blood (5ml, n=4) was cultured in the presence of human recombinant M-CSF (50ng/ml, R&D systems) replaced every other day for a week.
Floating cells were removed, and attached cells were cultured in serum-free medium with or without recombinant human VEGF-C (1μg/ml, PeproTech) for 3 sequential days. The conditioned medium was evaluated for heparanase and protease activity as described below. The in vitro experiments were performed in triplicate of three biological repeats.
Cathepsin and heparanase activity assay
Macrophages obtained from vehicle or PTX-treated Balb/c mice were harvested and cultured in serumfree medium at a concentration of 0.5x10 6 cells/ml. Cultured macrophages were treated with VEGF-C (1µg/ml) or VEGF-C and 31C1 (10µg/ml). Cathepsin inhibitor GB111-NH 2 (1µM) (Salpeter et al., 2015) was added to relevant controls 5 hours prior to medium collection. GB111-NH 2 is a cysteine cathepsin inhibitor that blocks the activity of cathepsins B, L and S (Salpeter et al., 2015) . Cathepsin probe GB123 was added to all samples 4 hours prior to medium collection, as previously described (Salpeter et al., 2015) . Conditioned medium was precipitated in 70% acetone for 4 hours. After centrifugation, pellets were resuspended in RIPA and filtered through an Amicon Ultra centrifugal filter unit Ultra-15. Protein content was quantified by Bradford and an equal amount of protein was resolved by SDS PAGE.
Fluorescent bands were analyzed by a Typhoon flatbed scanner (GE Healthcare: Excitation/Emission 630/670 nm). Intensities of the relevant bands were quantified by densitometry, using TotalLab Quant software (TotalLab, UK). Experiments were performed in triplicate, and the average of densitometry analyses was calculated.
Heparanase activity assay
Preparation of Na 2 35 SO 4 -labeled extracellular matrix (ECM)-coated 35-mm dishes and determination of heparanase activity were performed essentially as described in detail elsewhere (Bar-Ner et al., 1985; Vlodavsky et al., 1999) . Briefly, macrophage conditioned medium was incubated with 35 S-labeled ECM for 18 hours at 37°C. The incubation medium (1 ml) containing sulfate-labeled degradation fragments, was subjected to gel filtration on a Sepharose CL-6B column. Fractions (0.2 ml) were eluted with PBS and radioactivity was counted in a β-scintillation counter, Tri-Carb 2100TR (Packard Bioscience, CT).
Degradation fragments of heparan sulfate (HS) side chains produced by heparanase are eluted at 0.5 < Kav < 0.8 (peak II, fractions 18-25). Nearly intact HS proteoglycans (HSPGs) released from the ECM are eluted just after the V0 (Kav < 0.2, peak I, fractions 3-15). These high molecular weight products are released by proteases that cleave the HSPG core protein (Bar-Ner et al., 1985; Vlodavsky et al., 1999 ).
The results of the different fractions were plotted, and a representative graph from three biological replicates is provided. Subsequently, treatment with PTX and/or 31C1 was initiated, and three 3 days later, the primary tumors were harvested. Tumor sections were stained for podoplanin (red). DAPI was used to stain nuclei (blue). Tumors were harvested and sectioned. Tumor sections were stained with anti-podoplanin (red). DAPI was used to stain nuclei (blue). Scale bar = 200µm. The number of lymphatic vessels in the tumors was counted per field for each staining (n=10/ group).ns, non-significant; *p<0.05; **, 0.01≥p>0.001; ***, p≤0.001 using one way ANOVA followed by Tukey post-hoc test. , treatment with Clodrolip, PTX, and VEGF-C or the combination of the drugs was initiated at the schedule and doses indicated in Experimental Procedures. After 3 days, tumors were harvested and sections were prepared and stained for LYVE-1 (red) and DAPI (blue). The number of lymphatic vessels per field were counted (n=20 / group). (F) Plasma VEGF-C levels were evaluated by ELISA in non-tumor bearing Balb/c mice, 72 hours after they were depleted for macrophages, and 24 hours after they were treated with PTX (n=4 mice/group). *p<0.05; **, 0.01≥p>0.001; ***, p≤0.001 using one way ANOVA followed by Tukey post-hoc test. , treatment with Vehicle (Veh), E64, PTX or the combination of PTX+E64 was initiated in the schedule and doses described in Experimental Procedures. After 3 days, tumors were removed and tumor sections were stained for LYVE-1 (red) and DAPI (blue). The number of lymphatic vessels in tumor sections were counted per field (n=15 fields/group). Scale bar = 200µm. *p<0.05; ***, p≤0.001, using one way ANOVA followed by Tukey post-hoc test. ** 0.05<p<0.01, using two-tailed student t-test.
